CTEPH
2
Pipeline Programs
3
Companies
2
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
U
EDOXABANApproved
edoxaban
Unknown Companyoral
Competitive Landscape
2 companies ranked by most advanced pipeline stage
DS
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Daiichi SankyoEdoxaban
Merck & Co.dyspnea grade ≥ II according NYHA-WHO
Clinical Trials (2)
Total enrollment: 720 patients across 2 trials
Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)
Start: Mar 2021Est. completion: Jun 202374 patients
Phase 3Completed
Symptom-related Screening for Early Detection of CTEPH.
Start: Jan 2019Est. completion: Feb 2022646 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space